WilmerHale Advises Dyne Therapeutics in $168M Public Offering

WilmerHale Advises Dyne Therapeutics in $168M Public Offering

Client News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

WilmerHale represented Dyne Therapeutics, Inc., a biotechnology company focused on developing life-transforming therapies for patients with serious muscle diseases, in connection with its follow-on offering of common stock. The gross proceeds to Dyne were approximately $168 million, before deducting underwriting discounts and offering expenses. The offering priced on January 20, 2021 and closed on January 25, 2021.

The WilmerHale team representing Dyne was led by Stuart Falber, and included Scott Lunin, Mike Lopes, Erin Garrity, Lauren Roberts, Ciara Baker, Bruce Manheim and Heidi Treiber.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel